Co-Diagnostics, Inc. to Host Booth at ECCMID 2023 April 15-18 in Copenhagen, Denmark

Rhea-AI Summary

Co-Diagnostics, Inc. (NASDAQ: CODX) announced its participation in the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) from April 15-18, 2023, in Copenhagen, Denmark. The ECCMID is a key event in infectious diseases, attracting over 14,000 attendees and offering a hybrid format for greater accessibility. Co-Dx aims to connect with international customers for its real-time PCR products, including the upcoming Co-Dx PCR Home™ platform, which is currently under FDA review and not yet for sale. Visitors can find the company at Booth B4-04 to learn more about its innovative diagnostics technologies, which focus on nucleic acid detection and analysis.

SALT LAKE CITY, April 13, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) April 15-18, 2023, in Copenhagen, Denmark.

ECCMID is described as one of the most comprehensive and influential congresses in infectious diseases, bringing together international experts in related fields to present their latest findings, guidelines and experiences to an audience of over 14,000 colleagues. The congress also features a hybrid format, to facilitate an onsite and online experience for attendees allowing for remote and face-to-face opportunities.

Co-Dx believes that the congress will provide opportunities for Company representatives and distributors to interface with a wide cross-section of potential international customers for the Company's real-time PCR products. Attendees interested in learning more about the Company, including its upcoming Co-Dx PCR Home™ platform, are invited to visit Booth B4-04.

The Co-Dx PCR Home is subject to FDA review and is not available for sale.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR Home™ platform and to locate genetic markers for use in applications other than infectious disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-host-booth-at-eccmid-2023-april-15-18-in-copenhagen-denmark-301796491.html

SOURCE Co-Diagnostics

FAQ

What is Co-Diagnostics showcasing at ECCMID 2023?

Co-Diagnostics is showcasing its real-time PCR products and the upcoming Co-Dx PCR Home™ platform at ECCMID 2023.

When and where is the ECCMID 2023 event?

ECCMID 2023 is being held from April 15-18, 2023, in Copenhagen, Denmark.

What is the significance of the ECCMID congress?

ECCMID is one of the most influential congresses in infectious diseases, bringing together over 14,000 international experts.

Is the Co-Dx PCR Home™ platform available for purchase?

No, the Co-Dx PCR Home™ platform is subject to FDA review and is not available for sale.

Where can attendees find Co-Diagnostics at ECCMID?

Attendees can visit Co-Diagnostics at Booth B4-04 during ECCMID 2023.